Ezogabine treatment shown to reduce motor neuron excitability in ALS patients

Brian Wainger, MD, PhD, of the Healey Center for ALS at Massachusetts General Hospital presented initial, top-level results of a recently completed phase 2 clinical trial of ezogabine (also called retigabine) on Dec. 9 at the Motor...

Study: Age, race differences determine risk of stroke in women and men

A new study found that, between the ages of 45 and 74 years, white women were less likely to have a stroke than white men, but at age 75 and older, there was no difference in stroke risk between white women and men. In contrast, the...

Future of Alzheimer's therapy: What is the best approach?

According to the World Health Organization, approximately 50 million people around the world live with dementia, and approximately 60–70 percent have Alzheimer's disease. Current treatments for this condition address its symptoms, such as memory loss and behavioral...